We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+5.39%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
-$169M
(-10%)
Cap. Flow
-$49.5M
Cap. Flow
% of AUM
-3.29%
Top 10 Holdings %
Top 10 Hldgs %
63.08%
Holding
56
New
8
Increased
10
Reduced
5
Closed
4
Avg Time Held Equity + Options
1
year
Top 10 Avg Time Held Equity + Options
0.8
years
Top 20 Avg Time Held Equity + Options
0.9
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$57.8M |
| 2 |
Apellis Pharmaceuticals
APLS
|
+$27M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$25.5M |
| 4 |
BridgeBio Pharma
BBIO
|
+$20.9M |
| 5 |
AN2 Therapeutics
ANTX
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$167M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$58.8M |
| 3 |
Morphic Holding, Inc. Common Stock
MORF
|
+$15.2M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$10.2M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$6.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.83% |
| 2 | Miscellaneous | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Enliven Therapeutics
ELVN
$2.94B
| $14.3M | 0.95% |
1,050,483
+219,500
| +26% | +$3.7M |
2023 Q1
2 quarters
|
|
27
Tyra Biosciences
TYRA
$1.32B
| $14.2M | 0.94% |
1,028,013
| – | – |
2022 Q1
6 quarters
|
|
28
DELISTED
Soleno Therapeutics
SLNO
| $13.7M | 0.91% |
+464,937
| New | +$2.81M |
2023 Q3
0 quarters
|
|
|
29
Acadia Pharmaceuticals
ACAD
$3.39B
| $13.1M | 0.87% |
630,897
-226,441
| -26% | -$6.15M |
2022 Q3
4 quarters
|
|
30
Oric Pharmaceuticals
ORIC
$1.31B
| $13M | 0.86% |
2,142,855
| – | – |
2023 Q2
1 quarter
|
|
31
Autolus Therapeutics
AUTL
$458M
| $8.73M | 0.58% |
3,746,857
| – | – |
2022 Q1
6 quarters
|
|
|
32
Syndax Pharmaceuticals
SNDX
$1.21B
| $8.71M | 0.58% |
600,000
-3,108,838
| -84% | -$58.8M |
2022 Q1
6 quarters
|
|
33
Silence Therapeutics
SLN
$577M
| $8.66M | 0.58% |
881,173
| – | – |
2022 Q1
6 quarters
|
|
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $8.58M | 0.57% |
393,000
| – | – |
2022 Q1
6 quarters
|
|
35
DELISTED
Apogee Therapeutics
APGE
| $8.52M | 0.57% |
+400,000
| New | +$8.81M |
2023 Q3
0 quarters
|
|
36
MacroGenics
MGNX
$213M
| $8.4M | 0.56% |
1,803,204
| – | – |
2023 Q1
2 quarters
|
|
37
Agios Pharmaceuticals
AGIO
$1.91B
| $7.23M | 0.48% |
+292,002
| New | +$7.72M |
2023 Q3
0 quarters
|
|
38
Replimune Group
REPL
$1.1B
| $6.62M | 0.44% |
386,762
| – | – |
2022 Q1
6 quarters
|
|
39
Intellia Therapeutics
NTLA
$1.65B
| $6.44M | 0.43% |
203,684
| – | – |
2022 Q1
6 quarters
|
|
40
Prothena Corp
PRTA
$435M
| $6.17M | 0.41% |
127,900
| – | – |
2022 Q4
3 quarters
|
|
|
THRX
41
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $6.05M | 0.4% |
2,248,194
| – | – |
2022 Q4
3 quarters
|
|
42
Arvinas
ARVN
$467M
| $5.6M | 0.37% |
285,331
| – | – |
2022 Q1
6 quarters
|
|
43
DELISTED
bluebird bio
BLUE
| $5.2M | 0.35% |
85,495
| – | – |
2022 Q3
4 quarters
|
|
44
Edgewise Therapeutics
EWTX
$4.14B
| $4.86M | 0.32% |
849,022
+100,000
| +13% | +$680K |
2023 Q1
2 quarters
|
|
45
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $4.71M | 0.31% |
370,000
| – | – |
2023 Q2
1 quarter
|
|
46
Sutro Biopharma
STRO
$187M
| $2.71M | 0.18% |
78,000
| – | – |
2022 Q1
6 quarters
|
|
47
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $2.46M | 0.16% |
1,430,878
-970,836
| -40% | -$1.72M |
2022 Q1
6 quarters
|
|
48
Aclaris Therapeutics
ACRS
$506M
| $1.81M | 0.12% |
264,377
| – | – |
2022 Q1
6 quarters
|
|
|
49
PUT
Syndax Pharmaceuticals
SNDX
$1.21B
| $1.57M | 0.1% |
+600,000
| New | +$11.3M |
2023 Q3
0 quarters
|
|
50
ADC Therapeutics
ADCT
$197M
| $1.48M | 0.1% |
1,647,030
| – | – |
2023 Q1
2 quarters
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q3 2023 Portfolio in Review
As of Q3 2023, Frazier Life Sciences Management held 56 positions worth $1.51B, down 10% from $1.67B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Frazier Life Sciences Management withdrew a net $49.5M in Q3 2023, closing 4 positions and reducing 5 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $167M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Frazier Life Sciences Management opened a new position in Apellis Pharmaceuticals worth $23.4M.
- Frazier Life Sciences Management's largest Q3 2023 buy was Apellis Pharmaceuticals: 614,043 shares worth $23.4M.
- Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q3 2023, an estimated $57.8M increase.
- Frazier Life Sciences Management's biggest Q3 2023 reduction was Syndax Pharmaceuticals, cutting an estimated $58.8M.
- Frazier Life Sciences Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $167M.
- Frazier Life Sciences Management's ten largest holdings make up 63% of its $1.51B portfolio in Q3 2023.
- Frazier Life Sciences Management opened 8 new positions and closed 4 in Q3 2023.
- Frazier Life Sciences Management's portfolio value fell 10% quarter-over-quarter to $1.51B.
Based on Frazier Life Sciences Management's 13F filing for Q3 2023, filed 14 Nov 2023.